The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
The partners believe the platform, which captures high resolution images of CTCs and clusters, has potential applications in early cancer detection and disease monitoring.
CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.
The firms plan to build a workflow for CTC isolation directly from a patient's bloodstream for single-cell downstream molecular analysis such as sequencing, genotyping, or digital PCR.
The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The company highlighted efforts to expand the use of its tests in the analysis of cerebrospinal fluid, an area in which research collaborations have begun to yield some data.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
The submission data highlights Parsortix's ability to harvest circulating tumor cells from metastatic breast cancer patient blood samples for downstream analysis.
